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ABSTRACT 
 
We examined the following aspects of Maturity Onset 
Diabetes of the Young (MODY): prevalence, vascular 
complications, insulin secretion in offspring of 
MODY subjects, insulin resistance and whether 
MODY can be considered a distinct disease. 
 
We report a higher prevalence of MODY among 
Asian Indian patients. The prevalence rates of 
microvascular complications in MODY were found to 
be the same as in classical NIDDM patients. Glucose 
stimulated insulin and C-peptide responses were 
compared with non-diabetic controls. In MODY 
subjects, C-peptide responses were lower, whereas 
insulin responses were varied. Insulin secretion in 
offspring of MODY subjects was similarly evaluated, 
and abnormalities discovered even in these pre-
diabetic subjects. Using the euglycaemic clamp 
technique, MODY patients were found to be more 
insulin resistant than classical NIDDM patients. 
Further lines of evidence are needed to resolve 
whether MODY can be considered a distinct disease. 
  
INTRODUCTION 
 
The entity known as Maturity Onset Diabetes of the 
Young (MODY) was first described by Fajans (1) 
who first reported youth onset diabetics who were not 
dependent on insulin. Later Tattersall (2) from the 
king’s College, London, published a report entitled 
“Mild familial diabetes with dominant inheritance” 
where he described non-insulin-dependent diabetes 
presenting in youth. Soon a joint report followed from 
Tattersall and Fajans (3) where the term “MODY” 
was used for the first time using the first letters of 
“Maturity Onset Diabetes of Youth.” In this paper 
they set down the following criteria for the diagnosis 
of MODY:  
 
1. Age at diagnosis below 25 years  
 
2. Control of fasting hyperglycaemia without insulin 
for a minimum of 2 years and  
 
3. Absence of ketosis at any time  
 
Tattersall has recently suggested that the period 
without insulin should be extended to 5 years to 
completely exclude cases of IDDM who might 
initially respond to oral agents (4). It has also been 
suggested (4) that autosomal dominant inheritance 
should be used as a diagnostic criterion. However 
most studies in the literature have used the original 
criteria of Tattersall and Fajans. 
  
PREVALENCE OF MODY 
 
A number of reports from Europe and U.S.A. (5-8) 
have confirmed the existence of MODY. However, 
MODY is not a common form of diabetes among the 
while population (8). Recently it has been recognised 
that in certain communities of the world MODY type 
of diabetes is more common. This has been shown in 
Pima Indians (9), in the Nauru population (10) and 
more recently in Asian Indians in South Africa (11) 
and southern India (12). 
 
The actual prevalence of MODY in different 
populations still remains unknown. The only study 
that has examined the prevalence of MODY in the 
general population (8) found it to be 0.15%. In 
Tattersall’s original report (2), 1 in 200 patients 
attending the King’s College Hospital were found to 
have MODY type diabetes. In S. Africa, Jialal and co-
workers (11) using a cut-off point of 35 years, found 
that 10% of Indian NIDDM patients had MODY, a 
figure that was very much higher than in black and 
white communities living in S. Africa. In southern 
India we (12) found that 4.8% of our NIDDM patients 
at Madras had age at diagnosis below 25 years, in 
18.5% it was below 35 years and in almost 50% it 
was below 45 years. Thus, there appears to be a 
higher prevalence of MODY among Asian Indian 
patients. 
VASCULAR COMPLICATIONS IN MODY 
 
There is considerable controversy whether patients 
with MODY are prone to vascular complications. 
Tattersall (2) in his original report stated that 
microvascular complications were very uncommon in 
MODY. 
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Based on a large series, Fajans (13) reported that 
vascular complications occurred in his MODY 
patients with the same frequency as in classical 
NIDDM patients. Tattersall (4) then suggested that 
there could be different subgroups within MODY, 
such as autosomal dominant MODY and sporadic 
MODY and that the dominantly inherited MODY 
were protected from microvascular complications. 
 
During the last 6 years, several reports on 
microvascular complications in Asian Indian MODY 
patients have been published and these have been 
recently reviewed (14-16). At the Diabetes Research 
Centre, Madras, were registered a very large series of 
MODY patients (219 patients). This afforded a good 
opportunity to test the hypothesis that patients of 
MODY are protected from microvascular 
complications. We divided our 219 patients into three 
groups: MODY with definite autosomal dominant 
inheritance which included vertical transmission of 
diabetes through three or more generations; MODY 
patients who had a first degree relative with diabetes 
but in whom the dominant inheritance was not 
definite and finally a group of MODY with no family 
history of diabetes; sporadic or non-hereditary 
MODY. 
  
Table 1 shows the occurrence of vascular 
complications in the three subgroups of MODY. It 
can be seen that microvascular complications were 
equally common in all three subgroups of MODY 
including those with autosomal dominant inheritance 
(12). In a more recent study (17) we looked at 
vascular complications in 85 MODY patients who 
were watched for duration of diabetes with a group of 
classical NIDDM patients. It was found that there was 
no significant difference between the MODY and the 
classical NIDDM patients in prevalence rates of 
microvascular complications. Macrovascular 
complications, on the other hand, were less common 
among the MODY patients but this is hardly 
surprising considering their younger age. We 
therefore concluded that MODY were prone to 
microvascular complications just like the patients 
with classical NIDDM. Similar findings have been 
reported by Jialal et al from S. Africa (18). 
  
INSULIN SECRETION IN MODY 
 
Considerable heterogeneity has been described with 
respect to insulin responses to an oral glucose load in 
MODY (13). Thus families with normal as well as 
high insulin responses to glucose load have been 
described. Since it is known that approximately 50% 
of insulin undergoes extraction in the liver whereas 
the extraction of C-peptide is negligible, C-peptide 
assay gives us a better index of pancreatic beta cell 
secretion and simultaneous assay of insulin and C-
peptide gives information regarding pancreatic beta 
cell secretion as well as the peripheral
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Percentage distribution of vascular complications in MODY* 
 
   < 15 yr duration     > 15 yr duration 
 
    Definite   Possible     Definite   Possible 
  autosomal autosomal   Non-  autosomal autosomal   Non- 
   dominant  dominant hereditary  dominant  dominant hereditary 
   MODY   MODY  MODY  MODY  MODY  MODY 
   (n=43)    (n=82)   (n=34)   (n=16)  (n=35)   (n=9) 
 
BDR        2     11     6    25    41    44 
Proliferative       
retinopathy       2      2     3     6     6    11 
Nephropathy       7      5     6     6                        23                     33 
Neuropathy       2    12                 6                31                 49                  55 
IHD        0     4     0     6     14     0 
 
*Ref 12-Mohan et al. Diabetes Care 1985; 8: 371-74. 
BDR = Background Diabetic Retinopathy 
IHD = Ischemic Heart Disease; 
Difference between the three groups of MODY: not significant (Fischer’s exact probability test) 
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metabolism of insulin. We therefore performed 
simultaneous studies of insulin and C-peptide 
responses to glucose load in subjects with MODY and 
matched groups of control non-diabetic subjects. We 
found that C-peptide responses to glucose load were 
lower in MODY subjects, thereby providing evidence 
for decreased beta cell function in MODY (19). The 
insulin responses were varied, with some patients 
having normal responses and others low responses. 
This suggests that there could be an additional defect 
in the peripheral metabolism of insulin, most likely at 
the hepatic level. This could be a compensatory 
mechanism to maintain higher physiological 
circulating levels of insulin in the face of defective 
pancreatic beta cell function. Recent studies from S. 
Africa (20, 21) have confirmed our observations 
regarding defective beta cell secretion in MODY. 
  
INSULIN SECRETION IN OFFSPRING OF 
MODY SUBJECTS 
 
Having established that defective pancreatic beta cell 
secretion is a feature of MODY patients, our next 
objective was to see whether this defect in beta cell 
secretion precedes the onset of diabetes and if so, 
whether this could be used as an early biochemical 
marker for diabetes in MODY families. This is 
particularly relevant because in a disease with 
autosomal dominant inheritance only 50% of the 
offspring eventually develop diabetes if only one of 
the parents has the disease. It would therefore be 
useful if an early biochemical marker for diabetes 
could be found in these families. 
 
We studied offspring of MODY subjects (O-MODY) 
at a stage when they had normal glucose tolerance 
tests and examined their insulin and C-peptide 
responses to a glucose load. We were able to find 
evidence of abnormalities of insulin secretion even in 
these prediabetic subjects, suggesting that 
biochemical defects in MODY may be identifiable 
years before the onset of clinical diabetes. 
  
INSULIN RESISTANCE IN MODY 
 
Earlier studies on insulin resistance in MODY have 
produced conflicting results (23, 24). The 
euglycaemic clamp technique is widely recognised as 
one of the best ways of assessing insulin resistance 
(25). Mohan et al (26) performed euglycaemic clamps 
in MODY patients and healthy non-diabetic control 
subjects. The results showed that despite their 
younger age, MODY patients were more insulin 
resistant than classical NIDDM patients. It was 
therefore concluded that insulin resistance is a feature 
of MODY patients and this could be one of the 
factors responsible for the younger age at onset of 
diabetes that was observed in them. 
  
IS MODY A DISTINCT DISEASE? 
 
There are several lines of evidence to suggest that 
MODY is a distinct disease. Firstly MODY is the 
only form of diabetes today where a definite mode of 
inheritnace has been worked out (27). It is also the 
only type of diabetes for which a monogenic 
inheritance has been proposed. The prevalence of 
MODY varies in different ethnic groups. This is also 
suggestive of a distinct disease that has varying 
prevalence rates in different communities. 
 
There is also evidence to suggest that MODY could 
be just one end of the spectrum of NIDDM. The 
clinical features of MODY and the biochemical and 
hormonal characteristics do not show any differences 
from classical NIDDM. Genetic studies on MODY 
(10, 28) have drawn a blank so far, though admittedly 
these have been done on Caucasian subjects MODY. 
Very recently, in collaboration with Dr. Graham 
Hitman of the Royal London Hospital, Whitechapel, 
London, we (29) have looked at various gene markers 
in MODY. The results showed that there was a strong 
association with the class 3 allele of the insulin gene 
but the results were not different from that seen in 
classical NIDDM patients. Obviously more studies 
need to be done to resolve whether MODY is a 
separate disease or merely a continuum of NIDDM. 
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